Essential in vitro test before treatment of patients with intractable chronic lymphocytic leukemia.
About 23% of all chronic lymphocytic leukemic (CLL) patients have intractable CLL (ICLL) which is resistant to conventional therapy and has a poor prognosis. The ICLL patients complicate the determination of the efficacy of new therapeutic agents. An in vitro test is needed for the diagnosis of ICLL patients during the first examination.